ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1398	National Cancer Institute	Html	en	Skin Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.	skin cancer risk 0.467928 skin cancer 0.941497 cancer treatment 0.38312 cancer prevention trials 0.475588 skin cancer prevention 0.535336 prevention clinical trials 0.429013 protective factors 0.444137 following PDQ summaries 0.42969 PDQ cancer information 0.571591 recurrent nonmelanoma skin 0.412014 squamous cells 0.377891 Clinical Trials section 0.386332 clinical trials 0.585589 cancer information summary 0.499343 melanoma skin cancer 0.517983 breast cancer prevention 0.410906 cancer patients 0.382129 latest published information 0.38194 cancer risk factor 0.448186 NCI’s PDQ 0.391159 UV radiation 0.512203 NCI PDQ cancer 0.462016 basal cell carcinoma 0.591274 new cases 0.414085	PDQ Screening 0.380155 cancer risk factors 0.449906 Cancer prevention 0.618596 cancer protective factor 0.429755 new skin cancers 0.427053 new actinic keratoses 0.38071 Cancer Information Service 0.419558 slightly lower rates 0.381858 nonmelanoma skin cancers 0.666071 Prevention Editorial Board 0.428923 treatment clinical trials 0.387193 National Cancer Institute 0.507676 PDQ documents 0.381747 D. The skin 0.379577 new treatment 0.382048 Cancer Care page 0.40764 PDQ database 0.385226 PDQ summary 0.416284 melanoma prevention trials 0.402284 cancer clinical trials 0.430331 risk factors 0.646155 cancer information summaries 0.426847 nonmelanoma skin cancer 0.802884 comprehensive cancer information 0.42608	CLICK HERE
1450	National Cancer Institute	Html	en	Esophageal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for esophageal cancer.	population-based case-controlled study 0.533968 symptomatic gastroesophageal reflux 0.581421 columnar-lined esophagus 0.552922 curable neoplasms 0.466702 Barrett esophagus 0.931446 Gastric cardia adenocarcinoma 0.596066 lower esophageal sphincter 0.581561 standard histological evaluation 0.515998 gastroesophageal reflux 0.731721 squamous cell cancer 0.550703 surveillance method 0.472755 risk factors 0.526039 annual endoscopy 0.479023 esophageal squamous cell 0.594095 gastric acid production 0.530474 -relaxing drugs 0.467279 patients 0.488679 Barrett esophagus. 0.572924 GERD 0.55771 esophageal cancer incidence 0.58939 esophageal adenocarcinoma 0.818574 esophageal adenocarcinoma. 0.53156 human papillomavirus 0.478898 new cases 0.479464	gastroesophageal reflux disease 0.686421 low risk 0.472905 esophageal cancer 0.594243 H. pylori infections 0.535834 infection persisted. 0.473995 incidence rate ratio 0.524115 reflux esophagitis 0.501118 surgical resection 0.524265 low-grade dysplasia 0.493637 effective surveillance protocol 0.524901 surveillance endoscopy 0.490968 reflux symptoms 0.502651 high-grade dysplasia 0.535845 important epidemiological difference 0.530091 strong association 0.468389 expert gastrointestinal endoscopists 0.517855 duodenal ulcers 0.473231 risk factor 0.481047 Western countries 0.470134 successful resection 0.474238 cancer mortality. 0.469146 gastric infection 0.4806 risk 0.536679 intramucosal carcinoma 0.47033	CLICK HERE
1472	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Health Professional Version	Endometrial cancer is usually diagnosed at an early stage and can be treated with surgery. Learn about the symptoms, diagnosis, prognosis, staging, and treatment for early- and advanced-stage endometrial cancer in this expert-reviewed summary.	Obstet Gynecol 0.477047 papillary serous carcinoma 0.485706 endometrial cancer staging 0.480093 uterine cancer 0.371407 positive peritoneal cytology 0.407977 endometrial carcinoma 0.678904 normal endometrial 0.464798 endometrial cancer stage 0.512175 Int J Radiat 0.414383 Radiat Oncol Biol 0.512336 surgical staging 0.377398 oncology group study 0.48351 prognostic significance 0.39336 Natl Cancer Inst 0.399994 cell endometrial cancer 0.498772 Gynecologic Oncology Group 0.519757 endometrial hyperplasia 0.463477 Gynecol Oncol 0.817345 radiation therapy 0.404405 endometrial cancer 0.939144 early-stage endometrial cancer 0.512325 peritoneal cytology 0.432244 stage-1 endometrial carcinoma 0.468917 endometrial lining 0.46346 et al. 0.506597	clear cell endometrial 0.473365 progesterone receptor content 0.393655 stage endometrial cancer 0.540703 stage uterine papillary 0.382976 serous endometrial cancer 0.492942 type endometrial cancer 0.479957 endometrial tissue 0.462216 papillary serous cancer 0.3874 endometrial cancer patients 0.547475 early stage endometrial 0.515429 stage IIB patients 0.37429 risk endometrial adenocarcinoma 0.459895 Endometrial Cancer Study 0.48075 surgical-pathological risk factors 0.372575 endometrial canal 0.462243 comprehensive surgical staging 0.375341 Abstract 0.581453 progesterone receptor levels 0.46561 Clin Oncol 0.418943 surgical stage 0.412306 Oncol Biol Phys 0.518638 uterine papillary 0.386955 clinical stage 0.37895 vaginal brachytherapy 0.371898	CLICK HERE
1510	National Cancer Institute	Html	en	Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of small cell lung cancer.	Lung Cancer Cooperative 0.39126 small-cell lung cancer 0.985475 European Lung Cancer 0.390681 chemotherapy 0.385408 Engl J Med 0.425383 American Cancer Society 0.349857 Br J Cancer 0.382857 limited-stage small-cell lung 0.52446 Lung cancer deaths 0.390773 tobacco-specific lung carcinogen 0.37583 Lung Oncology Group 0.359221 Radiat Oncol Biol 0.383871 Lung Cancer Group 0.384497 oncology group study 0.36864 poor-prognosis small-cell lung 0.365771 Natl Cancer Inst 0.372388 cancer research campaign 0.352725 Council Lung Cancer 0.415558 stage small-cell lung 0.379153 Medical Research Council 0.386248 small-cell lung carcinoma 0.374311 et al. 0.448513 Lung Cancer Working 0.375734 extensive-disease small-cell lung 0.370168 Research Council Lung 0.400238	Cancer Epidemiol Biomarkers 0.349186 PUBMED Abstract 0.373095 limited-disease small-cell lung 0.382414 extensive small-cell lung 0.411565 limited-stage small cell 0.350265 small cell lung 0.655538 prophylactic cranial irradiation 0.394396 disease small-cell lung 0.396424 extensive-stage small-cell lung 0.398504 lung cancer patients 0.41432 Cancer Lung Cancer 0.412017 Abstract 0.488813 Clin Oncol 0.605439 cell lung carcinoma 0.379947 Oncol Biol Phys 0.385351 untreated small-cell lung 0.364584 lung cancer risk 0.385828 advanced small-cell lung 0.364607 Low-dose lung 0.356029 cell lung cancer 0.62237 better-prognosis small-cell lung 0.365507 multiple lung nodules 0.359952 thoracic radiotherapy 0.411609 limited small-cell lung 0.423802	CLICK HERE
1529	National Cancer Institute	Html	en	Male Breast Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of male breast cancer.	Clinical breast exam 0.284327 Breast Cancer Screening 0.314882 breast duct 0.265624 cancer spreads 0.259464 diagnose breast cancer 0.343362 malignant tumor cells 0.26356 body 0.314871 PDQ cancer information 0.299069 Inflammatory Male Breast 0.288019 clinical trials 0.336788 breast cancer stage 0.313107 cancer information summary 0.28338 clinical trial 0.259026 breast cancer prevention 0.329746 breast cancer patients 0.302243 lymph node biopsy 0.306018 sentinel lymph node 0.33726 Inflammatory breast cancer 0.359802 NCI PDQ cancer 0.260729 early localized breast 0.2726 lymph nodes 0.375271 breast carcinoma 0.267321 metastatic breast cancer 0.413709 radiation therapy 0.324944 treatment 0.354882	abnormal cells 0.280815 male breast cancer 0.548303 cancer cells 0.507692 Cancer Information Service 0.257721 specific cancer cells 0.266994 breast cancers 0.260852 National Cancer Institute 0.306996 Breast Cancer Treatment 0.32856 hormone therapy 0.286562 painful breast lesions 0.269444 lymph vessels 0.259581 new treatment 0.256083 breast cancer cells 0.328644 breast cancer 0.95341 Hereditary breast cancer 0.321208 chest wall 0.263619 Recurrent breast cancer 0.304665 IIIC breast cancer 0.305672 tumor 0.317659 treatment options 0.26574 cancer information summaries 0.256227 comprehensive cancer information 0.256173 information 0.313083 appropriate cancer treatment 0.261896	CLICK HERE
1695	National Cancer Institute	Html	en	High-Dose Vitamin C (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer.	ascorbic acid cause 0.642882 prostate cancer cell 0.630423 /IV ovarian cancer 0.57305 oral ascorbic acid 0.649173 vitamin C therapy 0.612109 vitamin C. 0.610223 cancer information summary 0.591614 weekly ascorbate infusions 0.607343 multiple myeloma patients 0.578578 ovarian cancer 0.574477 cancer patients 0.68661 vitamin 0.72459 high-dose vitamin 0.665873 oral vitamin 0.706163 significant adverse events 0.605455 high-dose IV ascorbate 0.593412 colon cancer cells 0.587994 ascorbic acid treatment 0.848969 metastatic colorectal cancer 0.572155 vitamin C supplements 0.616683 ascorbic acid 0.99701 study 0.585466 current clinical trials 0.571291 case series 0.594589 tumor volume 0.583085	pancreatic cancer patients 0.683645 dehydroascorbic acid 0.640204 terminal cancer patients 0.626123 cancer cells 0.588032 bortezomib growth inhibition 0.576885 high-dose ascorbic acid 0.717915 studies 0.596394 pharmacological ascorbate 0.581055 breast cancer cells. 0.579255 decrease cell proliferation 0.57116 ascorbic acid synthesis 0.660705 cancer cell lines. 0.642672 L-ascorbic acid 0.574809 intracellular ascorbic acid 0.648545 high-dose IV vitamin 0.658734 healthy volunteers 0.583492 inhibitory effect 0.590166 cancer cell death 0.591483 oxidized form 0.602818 cancer cell xenografts 0.58194 ascorbic acid. 0.583971 ascorbate 0.663468 tumor inhibitory effect 0.580256 cancer 0.692622	CLICK HERE
2057	National Cancer Institute	Html	es	Cáncer de hueso	Hoja informativa acerca del diagnóstico y tratamiento de los cánceres que se presentan en los huesos.	Lippincott Williams 0.528921 Pediatric Oncology 0.425852 DeVita VT 0.423199 Grandes avances 0.423263 Fischbach FT 0.422317 tejido óseo 0.925192 rayos x 0.477476 American Cancer Society 0.521554 página web guía 0.432205 7th ed 0.466045 altas dosis 0.425962 enfermedades infantiles congénitas 0.446544 Diagnostic Tests 0.424605 fosfatasa alcalina 0.483649 distintos tipos 0.471502 médico pregunta 0.42954 Pizzo P 0.423691 Estados Unidos 0.422015 survival among children 0.439442 Boice JD 0.42308 Rosenberg SA 0.420738 Fraumeni JF 0.42331 tumor óseo 0.736727 Schottenfeld D 0.42165	States SEER Program 0.439663 importante opción 0.422974 mejores formas 0.420225 pequeña cantidad 0.471903 editors.  cancer 0.434055 gammagrafía ósea 0.428461 O'Sullivan B 0.421908 Malawer MM 0.422909 Curtis RE 0.421362 probables beneficios 0.422945 National Cancer Institute 0.447941 4th ed 0.425929 Ries LAG 0.424185 Ewing Sarcoma Family 0.452617 Hellman S 0.421499 Dunning MB 0.422439 Retrieved March 0.423884 emission tomography 0.426368 enzima llamada 0.426279 cabo estudios 0.429851 Helman LJ 0.424392 Gurney JG 0.42319 Poplack DG 0.422887 Miller RW 0.421236	CLICK HERE
3448	National Cancer Institute	Html	es	Prevención del cáncer de ano (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ano, y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Malignancies Among Cancer 0.376997 long-term risk 0.317273 lesiones precursoras 0.331467 Goldstone S 0.318721 American Cancer Society 0.336812 NIH Pub 0.338006 Giuliano AR 0.319633 CA Cancer 0.335938 Engels EA 0.334211 nationwide cohort study 0.318123 Second cancers among 0.32229 new malignancies 0.372644 Frisch M 0.318875 anal hpv 0.38502 Ron E 0.319704 risk factors 0.340585 anal intraepithelial neoplasia 0.348272 Natl Cancer Inst 0.37761 papillomavirus-related gynecologic neoplasm 0.319719 cancers among 0.324258 human papillomavirus 0.471776 Anal carcinoma 0.320142 Cancer Epidemiology 0.319322 hpv infection 0.344517 SEER Cancer Statistics 0.322144	have sex with 0.39684 cohort study 0.328375 who have sex 0.393593 anal intra-epithelial neoplasia 0.321943 Fraumeni JF Jr 0.315722 Madeleine MM 0.330833 SEER Cancer 0.386157 SEER Cancer Registries 0.37953 Infect Dis 0.350074 Cancer Facts 0.318636 Curtis RE 0.320735 New Malignancies Among 0.340351 National Cancer Institute 0.584605 among men 0.315549 características histológicas 0.334238 Among Cancer Survivors 0.378869 papillomavirus-associated anal cancers 0.323075 Palefsky JM 0.334575 Freedman DM 0.321699 Cancer Survival Among 0.320203 anal cancer 0.954929 New malignancies following 0.338599 sexual practices 0.336294 cuello uterino 0.534342	CLICK HERE
15484	National Cancer Institute	Html	null	Cancer Moonshot Milestones	A collection of links to press releases, fact sheets, blog posts, and other materials documenting the latest Moonshot Initiative activities and milestones.			CLICK HERE
16709	National Cancer Institute	Html	es	ALCHEMIST (Estudios sobre la Secuenciación e Identificación de Marcadores para el Mejoramiento de la Terapia Adjuvante para el Cáncer de Pulmón): Preguntas y respuestas	ALCHEMIST comprende tres estudios clínicos integrados de medicina de precisión diseñados para identificar a personas con cáncer de pulmón en estadio inicial cuyos tumores tienen ciertos cambios genéticos poco comunes. También buscan evaluar si los tratamientos con medicamentos que combaten esos cambios moleculares pueden mejorar la supervivencia	Geoffrey Oxnard 0.313105 estudios clínicos alchemist 0.419541 genes egfr 0.537115 tumor carcinoide 0.318935 gen alk 0.998441 estudio alchemist 0.428836 cáncer nsclc 0.336759 Clinical Trials 0.385899 Washington University 0.311286 estudios alchemist hombres 0.406835 Dana-Farber Cancer Institute 0.323728 estadio ib 0.321816 largo plazo 0.311737 Cáncer ECOG-ACRIN 0.357818 Clinical Laboratory Improvement 0.323435 Cancer Enrichment Marker 0.325429 Cancer Genome Analysis 0.324094 Pasi A 0.313281 compañías farmacéuticas socias 0.322405 National Human Genome 0.322496 Instituto Nacional 0.327493	estadio iiia 0.321214 David E 0.311651 Terapia Adjuvante 0.312862 NCI Community Oncology 0.329248 Genoma Humano 0.311302 Ramaswamy Govindan 0.314989 gen egfr 0.724341 alchemist correspondientes 0.435182 Estados Unidos 0.373254 Texas Southwestern Medical 0.321883 cabo estudios 0.336005 principales objetivos 0.311051 Vysis ALK break-apart 0.345879 compañía response genetics 0.320675 estudios alchemist 0.840169 Astellas Pharma US 0.321115 Cancer Genomics 0.314435 Oncología NRG 0.312826 radioterapia posoperatorias 0.315764 Sequencing Trials 0.317534 Institutos Nacionales 0.331134	CLICK HERE